{"groups":[{"description":"GVAX vaccine\n\nParticipants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD.\n\nConditioning regimen: In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 4 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.\n\nAllogeneic Hematopoietic Stem Cell Transplant: Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor.\n\nGVHD Prevention:\n\n* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.\n* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant.\n\nGVAX: GVAX vaccination will begin between 30 to 45 days following participant's transplant, provided participant meets vaccination initiation criteria.","id":"FG000","title":"GVAX"},{"description":"Placebo vaccine\n\nParticipants in the placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD.\n\nConditioning regimen: In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 4 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.\n\nAllogeneic Hematopoietic Stem Cell Transplant: Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor.\n\nGVHD Prevention:\n\n* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.\n* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant.\n\nPlacebo: Placebo vaccination will begin between 30 to 45 days following participant's transplant, provided participant meets vaccination initiation criteria.","id":"FG001","title":"Placebo"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"59"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"27"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"32"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}